Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

Essentials• Rivaroxaban and dabigatran are substrates of the P‐glycoprotein (P‐gp)
encoded by the ABCB1 gene.• We tested the effect of ABCB1 polymorphisms and of a P‐gp …

Background Three novel direct oral anticoagulants (DOACs) have recently been registered
by the Food and Drug Administration and European Medicines Agency Commission …

The article discusses a guideline from the British Committee for Standards in Haematology,
focusing on the non-coumarin anticoagulants and its effect on haemostasis. It states that the …

Background: In recent years, several selectively acting anticoagulants, including the direct
thrombin inhibitors (DTI; argatroban, dabigatran) and the factor Xa inhibitors (rivaroxaban …

Dabigatran is an oral anticoagulant that is increasingly used for atrial fibrillation (AF).
Presently, many authorities state that routine laboratory coagulation monitoring is not …

Aim The aim of this study was to develop a PK/PD model to assess drug–drug interactions
between dabigatran and P‐gp modulators, using the example of clarithromycin, a strong …

OBJECTIVE: To assess the transplacental pharmacokinetics at term of the oral thrombin
inhibitor, dabigatran, and its prodrug, dabigatran etexilate mesylate, to estimate fetal drug …

We described the development and full validation of a rapid, high throughput sensible and
accurate LC method using tandem mass spectrometry detection for determining apixaban …

The effect of direct oral anticoagulants (DOACs) on laboratory tests dependent on the
production of their targets, factor IIa and factor Xa (FXa), is a well-known problem and can …